1;Preface;5 2;Contents;7 3;Contributors;11 4;Historical Overview;19 4.1;Tumor Angiogenesis: from Bench to Bedside;20 5;Mechanisms;46 5.1;Vasculogenesis and Angiogenesis in Development;47 5.2;Guidance of Vascular and Neuronal Network Formation;62 5.3;The Angiogenic Switch in Tumorigenesis;81 5.4;Pathophysiology and Clinical Implications of Vascular Endothelial Growth Factor;103 5.5;Regulation of Angiogenesis and Vascular Homeostasis Through the Angiopoietin / Tie System;123 5.6;Eph Receptors and Ephrins: Role in Vascular Development and Tumor Angiogenesis;135 5.7;The Role of the Neuropilins and Their Associated Plexin Receptors in Tumor Angiogenesis and Tumor Progression;149 5.8;Platelet- derived Growth Factor: Impact on Physiological and Tumor Angiogenesis;168 5.9;Hypoxia and Tumour Angiogenesis;183 5.10;Hypoxia and Angiogenesis in Glioblastomas;207 5.11;Endogenous Inhibitors of Angiogenesis;227 5.12;Thrombospondins and Angiogenesis;244 5.13;Molecular and Cellular Aspects of Heparanase;257 5.14;Vessel Maturation and Perivascular Cells;283 5.15;Adhesion Molecules in the Vascular Cell Cross- Talk;299 5.16;Homing and Differentiation of Endothelial Progenitor Cells;319 5.17;Molecular Players in Lymphangiogenesis;335 5.18;The Relationship Between Tumors and the Lymphatics: Consequences for Metastasis;351 5.19;Inflammation and Angiogenesis: Innate Immune Cells as Modulators of Tumor Vascularization;361 5.20;Arteriovenous Malformation in Mice and Men;373 6;Animal Models and Preclinical Anti- Angiogenic Studies;385 6.1;Vascular Endothelial Growth Factor Antibodies for Anti- Angiogenic Therapy;386 6.2;Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors for the Treatment of Cancer;403 6.3;Vascular Endothelial Growth Factor Receptor Antibodies for Anti- Angiogenic Therapy;432 6.4;Angiopoietin- 2 Antagonists for Anti- Angiogenic Therapy;460 6.5;Anti-Angiogenic Therapy with Thrombospondins;472 6.6;The Use of Orthotopic Models to Validate Antivascular Therapies for Cancer;483 6.7;Vascular Tumor Targeting;497 6.8;Molecular Imaging of Targets and Therapeutics in Tumour Angiogenesis;516 6.9;Imaging of Tumor Angiogenesis and Antiangiogenesis;534 6.10;Visualization of Microcirculation and Anti- Angiogenic Tumor Therapy;550 6.11;Cellular Actions of Angiogenesis Inhibitors on Blood Vessels;561 6.12;Antiangiogenic Therapy for Normalization of Tumor Vasculature and Microenvironment;581 6.13;Metronomic Antiangiogenic Chemotherapy: Questions and Answers;597 7;Anti- Angiogenic Tumor Therapy in Clinical Studies;612 7.1;The Development of Avastin;613 7.2;Clinical Development of Sorafenib ( BAY 43-9006), a VEGFR and RAF Inhibitor;656 7.3;Clinical Development of the VEGFR Signalling Inhibitor AZD2171;673 7.4;Clinical Development of Sunitinib Malate;689 7.5;The EGF( R) and VEGF( R) Pathways as Combined Targets for Anti- Angiogenesis Trials in Cancer Therapy;707 7.6;Imaging the Effect of Anti-Angiogenic Tumor Therapy in Clinical Studies;716 7.7;Vandetanib (;739 7.8;ZACTIMA;739 7.9;; ZD6474):;739 7.10;Preclinical and Clinical Development;739 7.11;Integrins: Targets for Anti-Angiogenic Therapy;758 7.12;Thalidomide in Multiple Myeloma;775 7.13;Surrogate Markers of Angiogenesis;791 7.14;Vascular Disrupting Agents in Cancer Therapy;805 8;Subject Index;826